Key result
Dipeptidyl peptidase-4 (DPP-4) inhibitors demonstrated potential cardiovascular protective effects in type 2 diabetes mellitus, including lowering blood pressure and improving lipid profiles.
Why the study?
Do DPP-4 inhibitors improve cardiovascular disease risk factors in patients with Type 2 Diabetes Mellitus?
Do DPP-4 inhibitors improve cardiovascular disease risk factors in patients with Type 2 Diabetes Mellitus?
DPP-4 inhibitors may offer cardiovascular protective effects beyond glycemic control in patients with type 2 diabetes, though long-term outcome trials are needed to confirm these benefits.
Answers are grounded in this paper and cite their sources.
May support CV risk factor management in type 2 diabetes; leaves open confirmation in dedicated outcome trials.
OBJECTIVE: To review the current literature investigating the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk factors of cardiovascular disease (CVD). METHODS: We conducted a search of PubMed and MEDLINE database, using the term DPP-4 inhibitor in combination with the following terms: metabolic syndrome, hypertension, dyslipidemia, insulin resistance, obesity, and CVD. We reviewed 100 relevant studies out of 227 articles, excluding single case reports, studies using animal models, and reports not written in English. We included 38 references in this review article. RESULTS: The majority of the recent clinical studies have demonstrated that DPP-4 inhibitors have beneficial effects on cardiovascular (CV) system. These agents may have the potential to lower blood pressure, improve lipid profile and endothelial dysfunction, decrease the macrophage-mediated inflammatory response, and prevent myocardial injury. CONCLUSION: DPP-4 inhibitors have some CV protective effects in type 2 diabetes mellitus (T2DM) in addition to their antidiabetic actions. Long-term outcome clinical trials are under way to investigate the effects of the DPP-4 inhibitors on the elevated CV risks in patients with T2DM. Further investigation in a large cohort is warranted to assess the exact mechanisms of CV protective effects of DPP-4 inhibitors.
No takes yet. Share an insight, caveat, or question.
Xiangbing Wang (2013) conducted a review in Type 2 Diabetes Mellitus. Dipeptidyl Peptidase-4 (DPP-4) inhibitors was evaluated on Cardiovascular disease risks and protective effects. Dipeptidyl peptidase-4 (DPP-4) inhibitors demonstrated potential cardiovascular protective effects in type 2 diabetes mellitus, including lowering blood pressure and improving lipid profiles.
Synapse has enriched 10 related papers. Consider them for comparative context: